BioSpace News Archive

Everest Medicines announces that its licensing partner, Gilead Sciences, Inc., reported positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® versus physicians’ choice of chemotherapy in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

Tumor DNA circulating in the bloodstream can help clinicians decide whether chemotherapy is right for their patients who have undergone surgery for stage II colon cancer, according to a breakthrough study published online in The New England Journal of Medicine and presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced EMA regulatory progress and tabelecleucel clinical outcomes.

New data presented at the 82nd Scientific Sessions of the American Diabetes Association® revealed the incidence of severe diabetic ketoacidosis among children with type 1 diabetes was significantly higher during the pandemic compared to pre-pandemic.

A new study reveals that diabetes is a potential risk factor for post-acute sequelae of COVID-19, also known as long COVID-19, a range of post-COVID-19 symptoms such as brain fog, skin conditions, depression, and shortness of breath.

A new study powered by artificial intelligence, Whole Body Digital Twin, reveals the highest reported rate of remission of type 2 diabetes to date.

Agendia, Inc. announced it will share findings in a poster discussion debuting initial data from its ImPrint test, a 53-gene signature in development, at the American Society of Clinical Oncology Annual Meeting 2022.

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced data from the ongoing Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies, is highlighted in a poster and oral discussion session at the American Society of Clinical Oncology 2022 Annual Meeting.

Kite, a Gilead Company, announced longer-term follow-up results from two pivotal studies of the CAR T-cell therapy Tecartus®.

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, presented new and updated results from the CARTITUDE clinical development program studying ciltacabtagene autoleucel in the treatment of multiple myeloma at the 2022 American Society of Clinical Oncology Annual Meeting.